Transplant assessment asks whether benefit outweighs lifelong risk
Heart transplantation replaces a failing heart with a donor organ for carefully selected patients with advanced disease not adequately helped by other treatment.
Evaluation is broader than heart function. Infection, cancer, lung pressure, kidney and liver function, frailty, adherence, support, finances and access to reliable lifelong follow-up all influence candidacy.
Eligibility, local allocation rules, donor availability and changing clinical status determine whether and when transplant can occur.
Who may be considered?
Specialist review may help when the diagnosis, symptoms and previous treatment create a focused question about heart transplant candidacy and planning.
- Advanced heart failure despite guideline-directed treatment.
- Repeated admissions, low output or inotrope dependence.
- Life-threatening ventricular arrhythmia not controlled by other therapy.
- Complex congenital or cardiomyopathic disease with no durable conventional option.
What the specialist team must confirm
The transplant team reviews heart-failure course, hemodynamics, imaging, exercise capacity, rhythm and device history, kidney and liver function, infection and cancer screening, pulmonary vascular resistance, nutrition, frailty, psychosocial support and medication reliability.
Key points for this treatment
From advanced heart failure to candidacy decision
The team compares transplant with ventricular assist devices, palliative approaches and any correctable cardiac cause.
Transplant creates a new lifelong care pathway
After surgery, immunosuppression, infection prevention, rejection surveillance and rehabilitation are coordinated closely. Doses and tests change over time.
Long-term care monitors graft function, coronary allograft disease, kidney injury, metabolic effects, infection and cancer risk. Reliable access to medicines and testing is essential.
Risks, limits and realistic expectations
Transplant is limited by donor access and carries risks of bleeding, stroke, graft dysfunction, rejection, serious infection, medication toxicity, cancer, coronary allograft disease and death. Travel and funding do not bypass allocation or ethical rules.
Severe breathlessness at rest, chest pain, fainting, confusion, low blood pressure or rapidly worsening swelling requires emergency local heart-failure care.